OCA
Total Payments
$6.1M
Transactions
7,066
Doctors
2,954
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $6.1M | 7,066 | 2,954 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.9M | 289 | 63.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $739,200 | 249 | 12.1% |
| Honoraria | $606,085 | 208 | 9.9% |
| Consulting Fee | $462,274 | 77 | 7.6% |
| Food and Beverage | $203,063 | 5,607 | 3.3% |
| Travel and Lodging | $152,328 | 547 | 2.5% |
| Space rental or facility fees (teaching hospital only) | $52,750 | 20 | 0.9% |
| Education | $8,404 | 69 | 0.1% |
Payments by Type
Research
$3.9M
289 transactions
General
$2.2M
6,777 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| General Research - Contracts | Intercept Pharmaceuticals, Inc. | $1.5M | 0 |
| PBC FOLD | Intercept Pharmaceuticals, Inc. | $1.4M | 0 |
| 303 | Intercept Pharmaceuticals, Inc. | $277,246 | 0 |
| 302 | Intercept Pharmaceuticals, Inc. | $269,530 | 0 |
| 207 | Intercept Pharmaceuticals, Inc. | $159,753 | 0 |
| 301 | Intercept Pharmaceuticals, Inc. | $137,463 | 0 |
| A Study of INT-747 6-ECDCA Monotherapy in Patients With Primary Biliary Cirrhosis NCT00570765 | Intercept Pharmaceuticals, Inc. | $115,513 | 0 |
| Phase 2 Study on Effects of Obeticholic Acid OCA on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis | Intercept Pharmaceuticals, Inc. | $26,370 | 0 |
| 209 | Intercept Pharmaceuticals, Inc. | $16,426 | 0 |
Top Doctors Receiving Payments for OCA — Page 3
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Fresno, CA | $13,161 | 21 |
| , M.D | Gastroenterology | Cincinnati, OH | $13,031 | 17 |
| , MD | Gastroenterology | Orange, CA | $12,986 | 11 |
| , MD | Hepatology | New York, NY | $12,652 | 10 |
| , MD | Gastroenterology | Birmingham, AL | $12,502 | 23 |
| , MD | Gastroenterology | New York, NY | $12,125 | 22 |
| , M.D | Hepatology | Sioux Falls, SD | $12,112 | 16 |
| , M.D | Gastroenterology | Detroit, MI | $11,957 | 18 |
| , MD | Internal Medicine | Royal Oak, MI | $11,834 | 12 |
| , MD | Gastroenterology | Atlanta, GA | $11,628 | 16 |
| , D.O | Gastroenterology | Hartford, CT | $11,541 | 21 |
| , M.D | Gastroenterology | New Haven, CT | $11,516 | 16 |
| , M.D | Hepatology | El Paso, TX | $11,457 | 17 |
| , DO | Gastroenterology | Allentown, PA | $11,317 | 14 |
| , M.D | Internal Medicine | Kansas City, KS | $11,297 | 18 |
| , MD | Hepatology | Cherry Hill, NJ | $11,284 | 32 |
| , M.D | Gastroenterology | Albany, NY | $11,231 | 18 |
| , MD | Gastroenterology | Hartford, CT | $10,938 | 20 |
| , M.D | Gastroenterology | Baltimore, MD | $10,778 | 17 |
| , M.D | Gastroenterology | West Hollywood, CA | $10,633 | 18 |
| , MD | Internal Medicine | Houston, TX | $10,576 | 18 |
| , MD PHD | Gastroenterology | Boston, MA | $9,969 | 6 |
| , MD, MPH, FACP | Hepatology | Philadelphia, PA | $9,949 | 18 |
| , M.D | Gastroenterology | Fall River, MA | $9,889 | 23 |
| , M.D | Gastroenterology | San Antonio, TX | $9,652 | 9 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $6.1M
- Total Doctors 2,954
- Transactions 7,066
About OCA
OCA is a drug associated with $6.1M in payments to 2,954 healthcare providers, recorded across 7,066 transactions in the CMS Open Payments database. The primary manufacturer is Intercept Pharmaceuticals, Inc..
Payment data is available from 2017 to 2017. In 2017, $6.1M was paid across 7,066 transactions to 2,954 doctors.
The most common payment nature for OCA is "Unspecified" ($3.9M, 63.5% of total).
OCA is associated with 9 research studies, including "General Research - Contracts" ($1.5M).